University of Calgary Study Uncovers Multiple Myeloma Immunotherapy Resistance Mechanisms in Canada's Largest Cohort

Canadian researchers at the University of Calgary's Arnie Charbonneau Cancer Institute have made a significant breakthrough in understanding why multiple myeloma immunotherapy resistance develops in patients treated with targeted T-cell engagers. Published in Nature Medicine, the study analyzed tumors from 21 relapsed patients—Canada's largest cohort of its kind—revealing complex, multimodal escape strategies employed by cancer cells. This work, funded by the Marathon of Hope Cancer Centres Network (MaRCo), highlights the power of collaborative academic research across Canadian institutions to tackle one of the most challenging blood cancers.

Multiple myeloma, a malignancy of plasma cells in the bone marrow, affects approximately 4,300 Canadians annually, making it the second most common blood cancer after non-Hodgkin lymphoma. Symptoms include bone pain, fatigue, anemia, kidney damage, and recurrent infections due to impaired antibody production. Despite advances, the disease remains incurable, with patients experiencing cycles of remission and relapse. This study sheds light on resistance to GPRC5D-targeted therapies, a promising class of immunotherapies following BCMA-targeted options.

Understanding Multiple Myeloma: From Biology to Clinical Challenge

Multiple myeloma (MM) arises from the uncontrolled proliferation of plasma cells, which normally produce antibodies to fight infections. In MM, these cells accumulate in the bone marrow, crowding out healthy blood cell production and secreting abnormal proteins (M-proteins) that damage organs. The Canadian Cancer Society reports that about 1,750 Canadians die from MM each year, with incidence rates steadily rising—projected to continue through 2026 due to aging populations and improved diagnostics.

Diagnosis involves blood tests (serum protein electrophoresis), urine analysis, bone marrow biopsy, and imaging like PET-CT or MRI to detect lytic bone lesions. Risk stratification uses cytogenetics: high-risk features include t(4;14), t(14;16), del(17p), or gain(1q). Standard frontline therapy combines proteasome inhibitors (e.g., bortezomib), immunomodulatory drugs (IMiDs like lenalidomide), steroids, and anti-CD38 monoclonal antibodies (daratumumab). For relapsed/refractory cases, immunotherapies have transformed outcomes.

The Rise of Targeted Immunotherapies in Multiple Myeloma

Immunotherapies leverage the patient's T cells to attack cancer. B-cell maturation antigen (BCMA)-targeted therapies, approved in Canada since 2022, include CAR-T cells (idecabtagene vicleucel/Abecma, ciltacabtagene autoleucel) and bispecific T-cell engagers (teclistamab, elranatamab). These bind BCMA on myeloma cells and CD3 on T cells, triggering cytotoxicity.

However, resistance emerges in 30-50% of patients within months, via BCMA loss (biallelic deletions, splicing variants) or T-cell exhaustion. Enter GPRC5D (G-protein-coupled receptor class C group 5 member D), a stem-cell antigen on myeloma cells but not normal tissues. Talquetamab (Janssen), approved in 2023, targets GPRC5D and shows 30-40% response rates post-BCMA failure. Yet, relapse occurs, prompting the University of Calgary team to investigate.

According to ASCO-Ontario Health guidelines updated in 2026, quadruplet induction (daratumumab + bortezomib + lenalidomide + dexamethasone) is standard, with bispecifics or CAR-T for early relapse. Canadian consensus emphasizes access via provincial funding.

MaRCo: Powering Canada's Largest Cancer Research Cohort

The Marathon of Hope Cancer Centres Network (MaRCo) unites researchers from universities across Alberta, Manitoba, Saskatchewan, and beyond, creating Canada's largest precision oncology cohort. With thousands of annotated samples, MaRCo enables pan-provincial studies impossible at single sites. The University of Calgary's Charbonneau Institute, home to a dedicated MM Research Program, leads with a tissue bank of over 4,500 samples.

This infrastructure powered the GPRC5D study, analyzing pre- and post-relapse tumors from 21 patients treated with talquetamab-like TCEs. As Drs. Nizar Bahlis, Paola Neri, and Holly Lee note, such networks exemplify how Canadian higher education drives clinical translation.

Photo by Vitaly Gariev on Unsplash

Unpacking the Study's Methods: Genomic Deep Dive

Led by Dr. Holly Lee and colleagues, the team performed whole-genome sequencing (WGS) at 100x depth on 28 samples (8 pre-therapy, 20 relapse). Single-cell RNA-seq (scRNA-seq), ATAC-seq, and flow cytometry assessed clonal evolution. Functional validation used patient-derived T cells against mutant cell lines expressing GPRC5D variants.

Structural modeling (AlphaFold2) predicted mutation impacts. This multi-omics approach revealed polyclonal resistance, where distinct subclones (up to 9 per tumor) evolve parallel escape paths.Full study in Nature Medicine details these innovations.

Key Resistance Mechanisms Revealed

• Biallelic Deletions: Focal (6-104 kb) or large losses at GPRC5D locus (chr12p13.1) eliminated expression in 40% of cases.
• SNV/Indel + Monoallelic Loss: 30% featured mutations (e.g., p.Asp239Asn disrupting TCE epitope; p.Tyr257Ser) plus deletion, clustering in GPCR motifs causing endoplasmic reticulum (ER) trapping—GPRC5D stuck inside cells.
• Epigenetic Silencing: In t(11;14) high-risk MM, promoter/enhancer chromatin closure halted transcription without DNA changes.

Polyclonality was striking: one patient had subclones with deletion, frameshift, and SNV converging on escape. Talquetamab lost efficacy against epitope mutants (275x IC50 rise), but bivalent TCEs like forimtamig retained potency.

Clinical Implications: Personalizing Therapy

Findings predict responders: baseline GPRC5D-low or t(11;14) patients risk epigenetic escape. Routine WGS over IHC detects SNVs. Strategies include:

• Multi-antigen TCEs (BCMA/GPRC5D).
• Epigenetic modifiers (HDAC inhibitors).
• Sequencing TCEs by epitope specificity.

Dr. Lee stated: “This blueprint identifies high-relapse risks and guides next-gen therapies.” MaRCo's immunogenomics project expands this to CAR-T/BiTE resistance.Canadian Cancer Society statistics underscore urgency: 5-year survival ~60%, but immunotherapy extends it.

Spotlight on University of Calgary's MM Leadership

The Charbonneau Institute's MM Program, with clinician-scientists like Bahlis (200+ publications), Neri, and Lee, pioneers resistance research. Funded by CIHR, Terry Fox, and MM foundations, it trains PhDs/postdocs in genomics/immunology. Collaborations with Würzburg, Roche enhance global impact.

Canada's MM ecosystem—Queen's OPDES guidelines, Terry Fox trials—positions universities as hubs for trials like MonumenTAL-3 (talquetamab combos).

Photo by Vitaly Gariev on Unsplash

Future Horizons: Overcoming Resistance

Trials test dual-targeting (e.g., JNJ-78284528 trispecific) and CRISPR-edited TCEs. MaRCo aims for single-cell atlases predicting exhaustion. Canadian guidelines evolve: 2026 ASCO updates endorse quadruplets, bispecifics early-line.

Academic jobs abound: research positions in MM genomics at UCalgary. This study exemplifies higher ed's role in precision oncology.

Stakeholder Perspectives and Patient Impact

Patients like those in Alberta's myeloma clinic report TCE skin/nail toxicities but deep responses. Experts like Dr. Bahlis emphasize: “MaRCo advances precision oncology.” Broader implications: reduce relapse, improve quality of life amid rising incidence.

Real-world data: median PFS 12.1 months for GPRC5D TCEs, per study. Actionable: genomic profiling at relapse.